Single-case experimental designs for bumetanide across neurodevelopmental disorders: BUDDI protocol

BACKGROUND: Bumetanide is a selective NKCC1 chloride importer antagonist which is being repurposed as a mechanism-based treatment for neurodevelopmental disorders (NDDs). Due to their specific actions, these kinds of interventions will only be effective in particular subsets of patients. To anticipa...

Descripción completa

Detalles Bibliográficos
Autores principales: Geertjens, Lisa, Cristian, Gianina, Haspels, Eva, Ramautar, Jennifer, van der Wilt, Gert Jan, Verhage, Matthijs, Bruining, Hilgo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9260985/
https://www.ncbi.nlm.nih.gov/pubmed/35799144
http://dx.doi.org/10.1186/s12888-022-04033-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9260985/
https://www.ncbi.nlm.nih.gov/pubmed/35799144
http://dx.doi.org/10.1186/s12888-022-04033-8

Ejemplares similares